Next Article in Journal
Ganoderma lucidum Ameliorates Non-Alcoholic Steatosis by Upregulating Energy Metabolizing Enzymes in the Liver
Next Article in Special Issue
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer
Previous Article in Journal
Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers
Previous Article in Special Issue
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
J. Clin. Med. 2018, 7(6), 151; https://doi.org/10.3390/jcm7060151

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

1
The Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia
2
Graduate Research School, University of New South Wales, Sydney, NSW 2052, Australia
3
Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia
4
Royal Prince Alfred Hospital, Camperdown, NSW 2006, Australia
5
School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia
6
The Chris O’Brien Lifehouse, Camperdown, NSW 2006, Australia
*
Author to whom correspondence should be addressed.
Received: 4 May 2018 / Revised: 8 June 2018 / Accepted: 12 June 2018 / Published: 14 June 2018
View Full-Text   |   Download PDF [272 KB, uploaded 15 June 2018]

Abstract

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice. View Full-Text
Keywords: non-small cell lung cancer; immunotherapy; checkpoint inhibitors non-small cell lung cancer; immunotherapy; checkpoint inhibitors
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Barnet, M.B.; Cooper, W.A.; Boyer, M.J.; Kao, S. Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. J. Clin. Med. 2018, 7, 151.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top